← Back to all trials
Completed
NCT05736640
Osseointegrated Transdermal Femoral Amputation Prostheses
Conditions: Osseointegrated Implants, Bone Mineral Density
Sex: All
Ages: 18 Years – 70 Years
Phase: NA
Enrollment: 6
Sponsor: University of Aarhus
Summary
Femur amputated patients often suffer from several problems with conventional socket prosthesis.
Some experience changes in gait, discomfort when sitting, altered skin conditions (infection, irritation, rashes, sweat), phantom pain or lack of stabilization between the prosthesis and the residual limb.
Many have a low score on "health-related quality of life" questionnaires (HRQL).Some femur amputated patients may be a candidate to osseointegrated prosthesis.
Osseointegrated prosthesis is an implant, where the fixture is inserted into the femur canal and an abutment screw, on which the leg-prostheses is inserted, protrudes the skin.
By this procedure the patient have a high score on HRQL and experience fewer problems.
They have improved gait, reduced discomfort when sitting, increased prosthetic use, and experience fewer skin and pain problems.Femur amputee patients formerly mobilized on socket prosthesis have a reduced bone mineral density in the affected femur and pelvis.The Phd-theses compromise of three studies.
The aim of the first study is to follow patients with oosseointegrated prosthesis before and after surgery with DXA-scans to monitor the BMD.
In the second study patients will be randomised to receive medical treatment with an RANKL-inhibitor, approved for treatment of osteoporosis, and monitored with DXA, microdialysis and radiostereometry.
Depending on the DXA-results patients in the third study may receive fast track rehabilitation.The hypothesis is that patients with osseointegrated prosthesis will have an increased BMD after surgery, 2 years follow up.
Patients receiving RANKL inhibitor will have increased BMD, stability of the prosthesis, and some receive fast-track rehabilitation due to high BMD.
Eligibility Criteria
Inclusion Criteria:Age between 18-70 yearsScheduled for OI-implant surgeryBody mass index <30Female patients of childbearing age must produce a negative pregnancy test and use effective contraceptioninformed consentExclusion Criteria:Diabetes with complicationAtherosclerosisSmokingDrug abuseTreatment with NSAID or cytostaticActive cancerLiver or kidney insufficiencyDementiaHip flexion contracture on the affected side >10 degreesBody weight >100 kgHypocalcaemiaContraindications to denosumab
Source: ClinicalTrials.gov (NCT05736640). StuddyBuddy aggregates publicly available trial information.